Member Info for Saxondale

Good to see it being put into progress . Faron were always going to be running this themselves from the presentations I've seen , so no surprise there is no Partner announcement . But perhaps this news suggests they are confident enough to start it knowing what other news may be coming ref Bexmab .

Took some profit from GGP and doubled my holding here this morning . Might as well take advantage while they muck about with the SP .

8 years ago the £7 SP equated to about £250m Mcap . They only had about 30m shares in issue . Today they have 114m and Mcap of £183m . It was about £200 Mcap a few days ago . So roughly , with a totally different treatment , and 8 years apart - the company has roughly the same valuation .

At £7 - most were expecting a big rerate upwards . It would have been worth much more that Mcap £250m

At £1.60 - surely - most are expecting a move upwards also with clinical success ? We should be worth much more than £183m

Personally it wont bother me if we do a massive placing - 80p - or £1.20 . Lets get this thing over the line .

I made good profit on the 85p placing , and we are further down the road since then with P2 in the bag - and now with better and stronger data too .

Bring it on -

I'd say the risk vs reward here is pretty good now . Yes the SP may get whacked with a placing - but firstly that may not even happen , but if it did - we could take advantage and it would pretty much nail on the future of the company - as it would get them to the market and profit finally .

I believe that this patent is based on and references that patent - This application claims the benefit of Finland Patent Application No. 20215080 filed on Jan. 25, 2021, the disclosure of which is incorporated herein in its entirety by reference.

However - my take is that this now adds to that by obtaining IP over the method and sequence in which the treatment is given .

Hence, it has been now found that both an agent capable of up-regulating CD73, such as type I interferon for the turnover of ATP into adenosine and a glucocorticoid are needed to be used in a sequential manner for best patient benefit in states of emergency and systemic inflammatory response. This highlights the necessity of administering within the narrow therapeutic window of both therapeutics and provides an insight into the natural pathway of endogenous interferon and cortisol reaction to protect internal organs and vascular system.

Thus, an object of the present invention is to provide a novel treatment strategy for an emergency medicine setting suitable for any indication which induces Systemic Inflammatory Response Syndromes (SIRS) and causes mortality from Multiple Organ Dysfunction Syndrome (MODS).

I would imagine that Traumakine has zero value in the current SP at present .

Anything would be a bonus - Dof D deal in US would be nice for starters !

Https://patents.justia.com/patent/12472235

Just noticed this patent - regarding the use of Traumakine ( Interferon ) actually with steroids - but just in the right order - ie Traumakine first - in order to up regulate CD73 - before damping any inflammation . Looks like they have worked out a formula to it to work , as unfortunately , the use of steroids is not going to go away - so it looks that they can work around it - if given first and promptly - not at end of life ( ventilator) stage .

Haven't read it all - and it gets very wordy - but its good to see that this crucial treatment may still have legs . So sad to see them fail back in 2019 just on the back of this issue , after so much science and money had been poured into it .

Also had a chunk . 3000 more to go in the pot . Come the new year , I'm fairly sure we'll have lift off . SSV surely must be just round the corner !! Might as well buy while it's in a slump . hasn't been this cheap since I ate my hat .

So we now have a good 6 months of time within which to get a Partner to sign .

I agree with BMH that they will be already well into the nitty gritty of negotiations now - hence the decision to issue the CLN - If they were preparing to raise themselves - they might as well just run the finances down and bite the bullet . This decision smells more like they see it as a 'bridging loan ' . Buyers are in the room - its just who will pay the asking price or blink first .

Not the boom, news I was hoping for before Xmas - but in my opinion it shows that they are close .

Hopefully my mining stocks will keep rising and I'll move some more in here shortly .

Under £1.80 is indeed an amazingly cheap entry point - should a deal be done in the next month or so .

And Petri Bono's comment here just highlights how much a a difference this treatment is for patients and the whole concept of treating patients compared to what they are currently getting .

“The new data on transfusion independence is clinically very meaningful. For MDS patients, freedom from regular transfusions is a major determinant of quality of life. By demonstrating that we can convert over half of frontline transfusion dependent patients to independence, while simultaneously driving deep molecular remissions in high-risk genetic subgroups, we are confirming that bexmarilimab acts on cancer cells and actively rehabilitates the bone marrow environment, which is a key differentiator compared to classical toxic drugs aiming to just kill cancer cells.”

Great positive update - data just gets stronger .

Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the frontline HR MDS

Median overall survival (mOS) with bexmarilimab and azacitidine in relapsed/refractory (r/r) HR-MDS patients reached 14.5 months (increased from 13.4 months

observed earlier), a significant improvement in a population with historically poor survival of only 5-6 months

In treatment-naïve patients with HR-MDS and TP53 mutation, the combination achieved a remarkable 70% complete remission (CR) rate

Deep responses allowed 50% of treatment-naïve TP53-mutated patients and 21% of r/r TP53-mutated patients to proceed to stem cell transplant (SCT)

For the first time, data shows 57% of frontline patients who were transfusion-dependent at baseline achieved transfusion independence, confirming restoration of healthy bone marrow function

Creeping up into close - 8.2% up with 670k traded on Naz .

Have a great weekend all .

Santhi , I think when the numbers get that big - its a backroom job . Someone dumping quarter of a million on open trades would collapse the price , and likewise someone trying to buy that amount would send it up like a rocket . Its a managed deal - either between two parties or just shuffling the shares around in order to keep the price where someone wants it for a while . We see that all the time at GGP - huge after hours trades - yet the SP doesn't budge all day .

IMO all it does is show a few footprints of big movers positioning for lift off .

If and when this kicks off - there will be humongous volume for a while - exciting times are coming .

Reminds me of Marku using the word ' Humungous ' a few times when questioned on where the SP could be with a deal .

Nice to see google is catching up - nothing came up yesterday on Bexnova - so I'm assuming my one little post has altered its search results lol

The Bexnova trial is a new name for the ongoing Phase II/III clinical trial of bexmarilimab (previously called Bexmab), an immunotherapy drug developed by Faron Pharmaceuticals

. The trial investigates bexmarilimab's effectiveness for treating hematological cancers, specifically relapsed or refractory myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Key information on the Bexnova (Bexmab) trial

What it treats: The trial focuses on hard-to-treat blood cancers, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These conditions have poor survival rates and limited treatment options.

What the drug does: Bexmarilimab is a monoclonal antibody designed to bind to a protein called Clever-1, which is found on immunosuppressive cells called macrophages. By targeting Clever-1, the drug is intended to inhibit tumor growth.

Encouraging results: Earlier data from the trial, when it was known as Bexmab, showed promising results. An 80% objective response rate was observed in a cohort of patients treated with bexmarilimab in combination with standard care, and the drug was well-tolerated.

Regulatory approval: Based on the positive results, the trial was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) and an Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

Timeline: In August 2025, Faron announced that the FDA had cleared the initiation of a new, registrational phase of the trial for higher-risk MDS. This suggests a move toward securing full market approval.

Trial name change

The name "Bexnova" was noted on recent Faron presentation slides, indicating that the company is rebranding its key trial asset. The new name is a sign of progress for the trial as it advances towards a new milestone in its development

3071 added .

That's definitely IT now .

When I'm this deep , i do start getting the old SNG worries again - but then realise that we already have the 'results' that the partner needs , and the cushion of such high efficacy means that the P3 endpoints will not be in doubt . No stone has been left unturned in order to understand the mechanism of Bex and the biomarkers required to select optimal patients . All the work over the last 10 years has got them here .

We really are on the cusp of the next big step for the company .

I noticed on their slides that P2/3 Bexmab-02 trial now has the new name ' BEXNOVA '

Random - or a nod of things to come - definition of NOVA in astronomical terms - a sudden appearance of a bright new star .

Juho's quip of ' one ring to rule them all ' years ago comes to mind .

Many a true word spoken in jest as they say .

Q&A very limited - obviously they don't want to field any probing questions at this point- but at least they gave us a hint of further drug development - with a Soluble Clever 1 engaging drug formulation - still in progress - with announcements to follow . Another string to their bow once that is made public . Soluble clever 1 was always going to something to deal with - and I'm at my limit of understanding here - but I remember Marku talking about it - being crucial to understanding the whole picture . So it looks like that has been well underway behind the scenes too .

Going back to the recent new data , the success with low blast count patients - and the ability of Bex to reach the hidden depths of the bone marrow ( something that other drugs are unable to do ) is something that they really stressed as being a game changer - and highlights again how unique this makes Bex - in its ability to reach its target . More proof - more understanding - higher price tag .

Just watched it - not done the Q&A yet - but Juhos summary - in my mind says to me - he is looking to do a deal that encompasses the value of the whole Bex concept - not just the MDS/AML situation - even though that is the key that has unlocked the door .

So - the business discussions in my opinion have taken so long and are deep , because I think he has been waiting to make a blanket deal for the platform to go forward . BexNova is ready to go - full protocol sorted etc - also Blaze - ready to go - just needs the nod . They have recruited staff etc - everything is primed to go .

You can't do all that and then hold them indefinitely - he must have plan B & C ready to deploy ( ie alternative fundraising ) .

Faron are at a crossroads where they can partner up with ONE big company to take this forward . It's BPs chance to take the whole pie .

Either way - they are going forward with this - that is for certain . Whoever steps up to fund BEXNOVA won't have to wait too long for payback - its all mapped out - no stopping once it starts .

They all seem to be chatting away as if funding had already been arranged .

Timo isn't chairman in the traditional sense I think is what he means . He's head of the board representing shareholders interests .

And he's obviously the biggest single shareholder - so has a vested interest in upholding shareholder value .

The fact that Timo has been here and adding for years has been a reassuring comfort for me during my whole period investing here . If he had smelt a rat or didn't see the value of being here - he would have made it known - or begun to leave - although that would have in itself decimated the SP in the process . Thank goodness he didn't have any crunch cash call during the last 6 years . Or if he did - we never got sacrificed to fix it .

What a superb long term backer for the company .

Anyway - by the looks of it his £30 million odd investment is finally about to start paying off .

- his last statement as to how funding is coming along - main stream being partnering or other fundraising - super active on all fronts - and he is ' Happy to Say that soon we will come out with what materializes '

Said with quite a wry smile on his face .

We are obviously very close to news , and he is happy .

With the latest data from Esmo - it must have helped potentially push final negotiations over the line .

As said before -there is nothing else to wait for - they can get going asap - and with the chance of accelerated approval after the first readout .

As long term investors , its hard not to get involved with the story and the people - otherwise why bother investing . Yes you need to stay objective and realistic . Over time - many of us have poured over every detail of the Bex program as it has evolved - and seen the calibre of scientists it has attracted . Funding is always the biggest obstacle to overcome - even when you have the best discovery on the planet .

I'm confident enough that we will get funding - so I'm adding and holding tight . I'm in no rush for the spoils - but at this price - we should do very well - even if the first deal they do isn't stratospheric . The best may still be yet to come with the solid tumours .

All we need is to get on the first rung of profitability - then the options are endless.